title: Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII.
abstract: A double-blind, placebo-controlled, cross-over study was conducted in 21 men with combined hyperlipoproteinaemia to examine if lipid-lowering treatment with gemfibrozil (10-12 weeks) affects blood coagulation and fibrin gel structure at rest or during mental stress. Gemfibrozil lowered plasma triglycerides by 57 +/- 4%, whereas high density lipoprotein (HDL) cholesterol increased by 22 +/- 5%. Gemfibrozil lowered the triglyceride content of low density lipoprotein (LDL). Gemfibrozil reduced the plasma concentrations of thrombin-antithrombin complex (TAT) and prothrombin fragment F1 + 2 (F1 + 2), both at rest and during mental stress. However, there were no effects of gemfibrozil treatment on the plasma concentrations of fibrinogen, factor VII antigen, activated factor VII (VIIa) or activated factor XII (XIIa), or on fibrin gel structure. Acute mental stress per se did not influence coagulation factors, reaction products or fibrin gel structure, or their responses to the study drug. Thus, gemfibrozil reduced thrombin generation in men with combined hyperlipoproteinaemia, without influencing the plasma levels of fibrinogen, VIIa and XIIa, or fibrin gel structure. Attenuation of thrombin generation may contribute to the primary-preventive effects of gemfibrozil on coronary heart disease.
authors.affiliation: Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden. broij@mb.ks.se
authors.forename: A
authors.initials: A
authors.lastname: Bröijersén
authors.forename: A
authors.initials: A
authors.lastname: Hamsten
authors.forename: A
authors.initials: A
authors.lastname: Silveira
authors.forename: K
authors.initials: K
authors.lastname: Fatah
authors.forename: A H
authors.initials: AH
authors.lastname: Goodall
authors.forename: M
authors.initials: M
authors.lastname: Eriksson
authors.forename: B
authors.initials: B
authors.lastname: Angelin
authors.forename: P
authors.initials: P
authors.lastname: Hjemdahl
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005167:Factor VII / Q000378:metabolism*; D015942:Factor VIIa / Q000378:metabolism; D015956:Factor XIIa / Q000378:metabolism; D005337:Fibrin / Q000737:chemistry*; D005340:Fibrinogen / Q000378:metabolism*; D005782:Gels; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013315:Stress, Psychological / Q000097:blood; D013917:Thrombin / Q000096:biosynthesis
chemical_list: D005782:Gels; D000960:Hypolipidemic Agents; D005167:Factor VII; D005337:Fibrin; D005340:Fibrinogen; D015942:Factor VIIa; D015956:Factor XIIa; D013917:Thrombin; D015248:Gemfibrozil